What is PEA and is it related to cannabis?

PEA (palmitoylethanolamide) is a naturally occurring fatty acid amide produced by the body and found in small amounts in foods like egg yolk, peanuts, and soybeans. It acts on the endocannabinoid system, but it is not a cannabis compound and has no psychoactive effects.

Can PEA replace NSAIDs for period pain?

This trial tested PEA alone and showed significant pain reduction versus placebo, but there is no direct head-to-head comparison with ibuprofen or naproxen yet. For severe dysmenorrhea, speak with a clinician about whether PEA might complement or partially replace existing pain management strategies.

How do I know if a product contains the same Levagen+ used in the study?

Look for 'Levagen+' declared on the label. Levagen+ is the trademarked PEA ingredient from Gencor Pacific. Products that list the ingredient by its generic name only may be using a different PEA source and may not carry the same clinical backing.

PEA 300mg Cut Period Pain by 25% in 2.5 Hours, Trial Shows

Participants recorded their period pain every 30 minutes. That precision was built into the design of a randomized, double-blind, placebo-controlled crossover trial conducted in Australia from May to December 2023. Women took a single dose of PEA (palmitoylethanolamide, Levagen+) 300 mg or placebo at the onset of menstrual pain and logged scores on a numerical rating scale for up to four hours. The results, published in Women & Health in February 2025, showed meaningful and measurable relief.

How the Trial Was Designed

The crossover structure is important here. Each participant served as their own control: one cycle on PEA, another on placebo. This design filters out individual pain tolerance differences that would otherwise muddy group comparisons.

Single dose at pain onset, with a second dose permitted after 2 hours if pain persisted
Pain measured every 30 minutes for up to 4 hours using the Numerical Rating Scale (NRS, 0-10)
Participants: adults 18 and older with menstrual pain

The Numbers

PEA produced significantly lower pain scores at 1.0, 1.5, 2.0, and 2.5 hours post-dose compared to placebo. The clearest signal arrived at 2.5 hours, where pain was approximately 25% lower than placebo.

Adverse events were equivalent between groups. A 300 mg single dose of Levagen+ showed a safety profile indistinguishable from placebo.

How PEA Works

PEA operates through the endocannabinoid system, the body’s internal network for regulating pain, inflammation, and immune response. The endocannabinoid system is the same network that cannabis compounds interact with, but PEA is not a cannabis derivative and produces no psychoactive effects.

More specifically, PEA suppresses mast cell and glial cell activation and binds to PPARα (peroxisome proliferator-activated receptor alpha), triggering anti-inflammatory signaling. Primary dysmenorrhea is driven in large part by prostaglandins, hormone-like compounds that trigger uterine muscle contractions and local inflammation at menstruation. PEA’s anti-inflammatory pathway is directly relevant to that mechanism.

The body produces PEA naturally and it is present in trace amounts in egg yolk, peanuts, and soybeans. Dietary intake alone, however, does not approach clinical doses.

About Levagen+

The PEA used in this trial was Levagen+ (Gencor Pacific Ltd), which also supported the research financially. Manufacturer-funded studies warrant scrutiny, but the crossover, double-blind design controls for the most common sources of bias. Gencor has also published separate data on Levagen+ in the context of gut microbiome-mediated immune health and topical skin barrier support, suggesting a multi-mechanism research strategy behind the ingredient.

Where PEA Sits Relative to NSAIDs

This trial did not compare PEA to ibuprofen or naproxen. Standard NSAIDs block the COX enzyme that produces prostaglandins directly, an established and fast-acting mechanism. PEA modulates the broader inflammatory environment through a different route.

For women who experience GI side effects from NSAIDs, or who prefer to limit their use of conventional pain medications, PEA at 300 mg represents an option with clinical backing and a clean safety profile in this trial. Whether PEA and NSAIDs work better in combination is an open research question.

Why This Trial Format Matters

Period pain affects an estimated 45 to 93% of people who menstruate, with a significant proportion reporting impact on daily function at school or work. Despite how common it is, treatment options have changed little: NSAIDs, hormonal contraception, and heat therapy are the standard recommendations.

The 30-minute measurement intervals in this trial were not just methodological precision for its own sake. They show when PEA starts working: statistically significant differences emerged as early as 1 hour post-dose. That timeline matters for an acute pain scenario where people need to know whether what they took is doing anything.

A 25% reduction in pain by hour 2.5 is not complete relief, but it is a clinically meaningful shift for a non-pharmaceutical option with no notable adverse events. That combination, meaningful effect plus tolerability, defines where PEA may fit into how period pain is managed going forward.

Source: Women & Health